Peter Berglund
Chief Scientific Officer HDT Bio
Seminars
Thursday 3rd December 2026
Fireside Chat: Comparing Personalized vs. Off-the-Shelf Cancer Vaccines to Choose the Right Strategy for the Right Indication
11:30 am
- Which indications are best suited to personalized cancer vaccines and how can they provide clinical advantage?
- What are the key trade-offs between clinical outcomes, manufacturing scalability, speed to patients, and development costs?
- What will determine the long-term commercial success and patient accessibility of personalized versus off-the-shelf cancer vaccines?
Thursday 3rd December 2026
Leveraging the LION Nanoformulation Technology to Unlock saRNA for the Development of Personalized Cancer Vaccines
4:30 pm
- Showcasing the potential of LION for improved safety, stability and precise extrahepatic delivery of cancer immunotherapies
- Uncovering the superior T-cell response achieved from saRNA/LION vaccines
- Highlighting how LION delivery can transform manufacture, cost and logistics including quick, LNP-free, bedside preparation of personalized cancer vaccines for patients
